S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
NYSE:AMRX

Amneal Pharmaceuticals Stock Forecast, Price & News

$4.10
-0.08 (-1.91%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.09
$4.38
50-Day Range
$4.18
$5.85
52-Week Range
$3.96
$7.45
Volume
983,129 shs
Average Volume
1.25 million shs
Market Capitalization
$1.24 billion
P/E Ratio
45.56
Dividend Yield
N/A
Beta
1.16
30 days | 90 days | 365 days | Advanced Chart
Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Amneal Pharmaceuticals logo

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Headlines

Amneal Obtains FDA Approval For Generic Durezol
November 19, 2021 |  markets.businessinsider.com
Amneal Pharmaceuticals (NYSE:AMRX) Releases FY 2021 Earnings Guidance
November 10, 2021 |  americanbankingnews.com
Amneal Pharmaceuticals (AMRX) Tops Q3 Earnings Estimates
November 3, 2021 |  finance.yahoo.com
Mark Cuban-Owned Company To Launch Pharmacy Benefit Management Services
October 25, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
6,000
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.99 billion
Cash Flow
$1.35 per share
Book Value
$1.15 per share

Profitability

Net Income
$91.06 million
Pretax Margin
2.04%

Debt

Price-To-Earnings

Miscellaneous

Free Float
221,172,000
Market Cap
$1.24 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/25/2022

MarketRank

Overall MarketRank

1.96 out of 5 stars

Medical Sector

666th out of 1,392 stocks

Pharmaceutical Preparations Industry

313th out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

Is Amneal Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amneal Pharmaceuticals stock.
View analyst ratings for Amneal Pharmaceuticals
or view top-rated stocks.

How has Amneal Pharmaceuticals' stock been impacted by Coronavirus?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMRX shares have increased by 26.2% and is now trading at $4.10.
View which stocks have been most impacted by COVID-19
.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, February 25th 2022.
View our earnings forecast for Amneal Pharmaceuticals
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) released its quarterly earnings results on Wednesday, November, 3rd. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.01. The business earned $528.30 million during the quarter, compared to analyst estimates of $544.08 million. Amneal Pharmaceuticals had a net margin of 0.68% and a trailing twelve-month return on equity of 61.08%. The business's quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.16 earnings per share.
View Amneal Pharmaceuticals' earnings history
.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided earnings per share guidance of $0.780-$0.880 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.880. The company issued revenue guidance of $2.10 billion-$2.10 billion, compared to the consensus revenue estimate of $2.14 billion.

What price target have analysts set for AMRX?

5 analysts have issued 1 year price objectives for Amneal Pharmaceuticals' shares. Their forecasts range from $5.50 to $9.00. On average, they anticipate Amneal Pharmaceuticals' stock price to reach $7.40 in the next twelve months. This suggests a possible upside of 80.5% from the stock's current price.
View analysts' price targets for Amneal Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Chintu Patel, Co-Chief Executive Officer & Director
  • Chirag K. Patel, President & Co-Chief Executive Officer & Director
  • Andrew S. Boyer, Executive Vice President-Commercial Operations
  • Anastasios G. Konidaris, Chief Financial Officer & Senior Vice President
  • Nikita Shah, Chief Human Resources Officer & Senior VP

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals CEO Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among Amneal Pharmaceuticals' employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.30%), Eversept Partners LP (2.27%), Point72 Asset Management L.P. (1.24%), Neuberger Berman Group LLC (1.10%), Geode Capital Management LLC (0.54%) and Dimensional Fund Advisors LP (0.45%). Company insiders that own Amneal Pharmaceuticals stock include Chintu Patel, Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco and Paul M Meister.
View institutional ownership trends for Amneal Pharmaceuticals
.

Which institutional investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Marshall Wace LLP, Geode Capital Management LLC, Arrowstreet Capital Limited Partnership, BlackRock Inc., Invesco Ltd., Neuberger Berman Group LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Amneal Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Amneal Pharmaceuticals stock?

AMRX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Eversept Partners LP, Russell Investments Group Ltd., Two Sigma Investments LP, Goldman Sachs Group Inc., Morgan Stanley, Two Sigma Advisers LP, and Hillsdale Investment Management Inc.. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Chintu Patel, Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, and Paul M Meister.
View insider buying and selling activity for Amneal Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $4.10.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals has a market capitalization of $1.24 billion and generates $1.99 billion in revenue each year. The company earns $91.06 million in net income (profit) each year or $0.09 on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

Amneal Pharmaceuticals employs 6,000 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

Where are Amneal Pharmaceuticals' headquarters?

Amneal Pharmaceuticals is headquartered at 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at (908) 947-3120, via email at [email protected], or via fax at 908-947-3146.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.